Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Nintedanib with Add-on Pirfenidone in IPF
NCT02579603Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2015
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 4 trial of nintedanib, pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Oct 2015; status: completed.
02
Drugs
nintedanibpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02579603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579603.